Usefulness of Serum Carcinoembryonic Antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: A prospective cohort study

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Arrieta, Oscar ^a,b   Villarreal Garza, Cynthia ^a   Martínez Barrera, Luis ^c   Morales, Marcelino ^a   Dorantes Gallareta, Yuzmiren ^a   Peña Curiel, Omar ^a   Contreras Reyes, Susana ^a   Macedo Pérez, Eleazar Omar ^a   Alatorre Alexander, Jorge ^a,b  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Carcinoembryonic antigen; Non small cell lung cancer; Prognosis; Response prediction; Tumor markers

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84878006279     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-254     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. Makitaro R, Paakko P, Huhti E, Bloigu R, Kinnula VL. Prospective population-based study on the survival of patients with lung cancer. Eur Respir J 2002, 19(6):1087-1092. 10.1183/09031936.02.00048302, 12108861.
3. Scagliotti GV, De Marinis F, Rinaldi M. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20(21):4285-4291. 10.1200/JCO.2002.02.068, 12409326.
4. Schiller JH, Harrington D, Belani CP. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346(2):92-98. 10.1056/NEJMoa011954, 11784875.
5. Paesmans M, Sculier JP, Libert P. Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party. Eur J Cancer 1997, 33(14):2326-2332. 10.1016/S0959-8049(97)00325-0, 9616276.
6. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000, 82(9):1535-1538. 2363391, 10789720.
7. Matsuoka K, Sumitomo S, Misaki N. Prognostic factors in patients with pathologic T1-2N1M0 disease in non-small cell carcinoma of the lung. J Thorac Oncol 2007, 2(12):1098-1102. 10.1097/JTO.0b013e31815ba227, 18090581.
8. Okada M, Nishio W, Sakamoto T. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg 2004, 78(1):216-221. 10.1016/j.athoracsur.2004.02.009, 15223432.
9. Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. Anticancer Res 2010, 30(7):3099-3102.
10. Tomita M, Matsuzaki Y, Edagawa M, Shimizu T, Hara M, Onitsuka T. Prognostic significance of preoperative serum carcinoembryonic antigen level in lung adenocarcinoma but not squamous cell carcinoma. Ann Thorac Cardiovasc Surg 2004, 10(2):76-80.
11. Blankenburg F, Hatz R, Nagel D. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score. Tumour Biol 2008, 29(4):272-277. 10.1159/000152945, 18781099.
12. Sakao Y, Tomimitsu S, Takeda Y, Natsuaki M, Itoh T. Carcinoembryonic antigen as a predictive factor for postoperative tumor relapse in early-stage lung adenocarcinoma. Eur J Cardiothorac Surg 2004, 25(4):520-522. 10.1016/j.ejcts.2004.01.029, 15037265.
13. Sawabata N, Ohta M, Takeda S. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg 2002, 74(1):174-179. 10.1016/S0003-4975(02)03662-7, 12118753.
14. Hanagiri T, Sugaya M, Takenaka M. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer 2011, 74(1):112-117. 10.1016/j.lungcan.2011.02.001, 21397974.
15. Ardizzoni A, Cafferata MA, Tiseo M. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer 2006, 107(12):2842-2849. 10.1002/cncr.22330, 17103443.
16. Arrieta O, Saavedra-Perez D, Kuri R. Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. BMC Cancer 2009, 9:119. 10.1186/1471-2407-9-119, 2679041, 19386089.
17. Eisenhauer EA, Therasse P, Bogaerts J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247. 10.1016/j.ejca.2008.10.026, 19097774.
18. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol Apr 1999, 9(2):67-81.
19. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002, 122(3):1037-1057. 10.1378/chest.122.3.1037, 12226051.
20. Desch CE, Benson AB, Somerfield MR. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005, 23(33):8512-8519. 10.1200/JCO.2005.04.0063, 16260687.
21. Lin JK, Lin CC, Yang SH. Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patients with curable colorectal cancer. Int J Colorectal Dis 2011, 26(9):1135-1141. 10.1007/s00384-011-1209-5, 21538056.
22. Lee WS, Baek JH, Kim KK, Park YH. The prognostic significant of percentage drop in serum CEA post curative resection for colon cancer. Surg Onco 2012, 21(1):45-51.
23. Iwanicki-Caron I, Di Fiore F, Roque I. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol 2008, 26(22):3681-3686. 10.1200/JCO.2007.15.0904, 18669452.
24. Kawachi R, Nakazato Y, Takei H, Koshi-ishi Y, Goya T. Clinical significance of preoperative carcinoembryonic antigen level for clinical stage I non-small cell lung cancer: can preoperative carcinoembryonic antigen level predict pathological stage?. Interact Cardiovasc Thorac Surg 2009, 9(2):199-202. 10.1510/icvts.2009.206698, 19457896.
25. Nisman B, Lafair J, Heching N. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?. Cancer 1998, 82(10):1850-1859. 10.1002/(SICI)1097-0142(19980515)82:10<1850::AID-CNCR6>3.0.CO;2-R, 9587116.
26. Foa P, Fornier M, Miceli R. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res 1999, 19(4C):3613-3618.
27. Reinmuth N, Brandt B, Semik M. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 2002, 36(3):265-270. 10.1016/S0169-5002(02)00009-0, 12009236.
28. Erasmus JJ, Gladish GW, Broemeling L. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003, 21(13):2574-2582. 10.1200/JCO.2003.01.144, 12829678.
29. Ishiguro F, Fukui T, Mori S. Serum carcinoembryonic antigen level as a surrogate marker for the evaluation of tumor response to chemotherapy in nonsmall cell lung cancer. Ann Thorac Cardiovasc Surg 2010, 16(4):242-247.
30. Chiu CH, Shih YN, Tsai CM, Liou JL, Chen YM, Perng RP. Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib. Lung Cancer 2007, 57(2):213-221. 10.1016/j.lungcan.2007.02.016, 17449138.
31. Xu CA, Su H, Liu JL, Li L, Zou HW. Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor. Zhonghua Zhong Liu Za Zhi 2011, 33(6):436-441.
32. Okamoto T, Nakamura T, Ikeda J. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. Eur J Cancer 2005, 41(9):1286-1290. 10.1016/j.ejca.2005.03.011, 15939264.
33. Jung M, Kim SH, Hong S. Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Yonsei Med J 2012, 53(5):931-939. 10.3349/ymj.2012.53.5.931, 3423836, 22869475.
34. Jin B, Huang AM, Zhong RB, Han BH. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer. Chemotherapy 2010, 56(6):417-423. 10.1159/000317580, 21079400.
35. Matsuoka K, Sumitomo S, Nakashima N, Nakajima D, Misaki N. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2007, 32(3):435-439. 10.1016/j.ejcts.2007.05.014, 17611117.
36. Pujol JL, Molinier O, Ebert W. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004, 90(11):2097-2105. 2409493, 15150567.
37. Vollmer RT, Govindan R, Graziano SL. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. Clin Cancer Res 2003, 9(5):1728-1733.